Pragmatic Considerations in Switching to  Semaglutide for Obesity Management: Real- World Perspectives

Dr SANJAY KALRA; Dr JEYAKANTHA RATNASINGAM; Dr SIEW PHENG CHAN; Dr DICKY L TAHAPARY; Dr CHAICHARN DEEROCHANAWONG; Dr VIVIEN LIM; Dr KETUT SUASTIKA; Dr JEREMY JONES ROBLES; Dr SHAHJADA SELIM; Dr NITIN KAPOOR

doi:10.59793/bzsxq840

Pragmatic Considerations in Switching to Semaglutide for Obesity Management: Real- World Perspectives

Authors

Dr SANJAY KALRA Treasurer, International Society of Endocrinology (ISE); Vice President, South Asian Obesity Forum (SOF); Bharti Hospital, Karnal, Haryana, India
Dr JEYAKANTHA RATNASINGAM Professor of Medicine & Endocrinology, Senior Consultant Endocrinologist & Head of Endocrine Division, Dept. of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
Dr SIEW PHENG CHAN ‡ Professor Emeritus of Endocrine Medicine, Universiti Malaya; Consultant Endocrinologist, Subang Jaya Medical Centre, Malaysia
Dr DICKY L TAHAPARY Division of Endocrinology, Metabolism and Diabetes, Dept. of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr Cipto Mangunkusumo National Referral Hospital, Jakarta, Indonesia; Metabolic, Cardiovascular and Aging Cluster, The Indonesian Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Dr CHAICHARN DEEROCHANAWONG College of Medicine, Rangsit University, Thailand
Dr VIVIEN LIM Gleneagles Hospital, Singapore
Dr KETUT SUASTIKA Division of Endocrinology and Metabolism, Dept. of Internal Medicine, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia; Division of Endocrinology, Metabolism and Diabetes, Dept. of Internal Medicine, Faculty of Medicine, Mahasaraswati University, Denpasar, Bali, Indonesia
Dr JEREMY JONES ROBLES Section of Adult Endocrinology, Diabetes and Metabolism, Chong Hua Hospital, Cebu City, Philippines.
Dr SHAHJADA SELIM Associate Professor, Dept. of Endocrinology, Bangladesh Medical University, Bangladesh
Dr NITIN KAPOOR Dept. of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India

DOI:

https://doi.org/10.59793/bzsxq840

Keywords:

Obesity,, switching,, semaglutide,, tirzepatide,, dose conversion,, guidance,, individualized care

Abstract

Incretin-based therapies have transformed the management of obesity and related cardiometabolic diseases. With the increasing
availability of agents such as semaglutide and tirzepatide, switches between therapies are occurring in clinical practice despite
the absence of formal randomized evidence guiding such transitions. This review outlines pragmatic, experience-based
considerations for switching from tirzepatide to semaglutide including clinical rationale, dose conversion approaches, titration
strategies, and cost-sensitive implementation. These practical insights aim to support clinicians in optimizing individualized,
safe, and cost-effective obesity management.

Downloads

Published

2026-05-01

Issue

Vol. 36 No. 11 (2026)

Section

Viewpoint

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All open access articles published in IJCP are distributed under the terms of the CC BY-NC 4.0 license (Creative Commons Attribution-Non-Commercial 4.0 International Public License). This license permits unrestricted use, distribution, and reproduction of the articles in any medium for non-commercial purposes, provided that:  The original authorship is properly and fully attributed. The IJCP is cited as the original place of publication with correct citation details.  If an original work is reproduced or disseminated in part or as a derivative work, this must be clearly indicated.  No articles are reproduced for commercial use without prior consent from the IJCP. All licensing requests and permissions for commercial use will be managed by the Publisher.

How to Cite

Pragmatic Considerations in Switching to Semaglutide for Obesity Management: Real- World Perspectives. (2026). Indian Journal Of Clinical Practice, 36(11), 38-41. https://doi.org/10.59793/bzsxq840